Format

Send to

Choose Destination
Matrix Biol. 2018 Aug;68-69:318-332. doi: 10.1016/j.matbio.2017.12.013. Epub 2017 Dec 30.

Renal fibrosis: Recent translational aspects.

Author information

1
Inserm UMR_S 1155 Des Maladies Rénales Rares Aux Maladies Fréquentes, Remodelage et Réparation, France; AP-HP, Service de Médecine Interne et Immunologie Clinique, Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France, Université Paris Sud, France. Electronic address: helene.francois@aphp.fr.
2
Inserm UMR_S 1155 Des Maladies Rénales Rares Aux Maladies Fréquentes, Remodelage et Réparation, France.

Abstract

Renal fibrogenesis is the common final pathway to all renal injuries that consequently leads to Chronic Kidney Disease (CKD). Renal fibrogenesis corresponds to the replacement of renal functional tissue by extra-cellular matrix proteins, mainly collagens, that ultimately impairs kidney function. Blockade of the renin angiotensin system by Angiotensin Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs) was the first strategy that proved efficient to blunt the development of renal fibrogenesis independently of its systemic action on blood pressure. Although this strategy has been published 20years ago, there is to date no novel therapeutic targets that are both safe and efficient in hindering renal fibrogenesis and CKD in humans, nor there is any new biomarker to precisely quantify this process. In our review, we will focus on the most recent pathways leading to fibrogenesis which have a high therapeutic potential in humans and on the most promising biomarkers of renal fibrosis.

KEYWORDS:

Biomarker; CB1; CKD; Collagen degradation products; DDR1; Endothelin-receptor A blockers; Galectin-3; Periostin; Pirfenidone; Renal fibrosis; TGFβ; Targeted therapy; Urinary exosomes; miRNA

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center